

Tourette Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/T32C09C0F7C3EN.html>

Date: February 2022

Pages: 46

Price: US\$ 2,000.00 (Single User License)

ID: T32C09C0F7C3EN

Abstracts

Tourette Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Tourette Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Tourette Syndrome (Central Nervous System) pipeline landscape.

Tourette syndrome (TS) is a neurological disorder characterized by repetitive, stereotyped, involuntary movements and vocalizations called tics. Symptoms include eye blinking and other eye movements, facial grimacing, shoulder shrugging, and head or shoulder jerking. Other symptoms include touching the nose, smelling objects, flapping the arms, and hopping. The predisposing factors include age. Males are about three to four times more likely than females to develop Tourette syndrome. Treatment includes antidepressants, stimulant medications and behavior therapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Tourette Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Tourette Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of

administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Tourette Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Tourette Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecule, respectively.

Tourette Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Tourette Syndrome (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Tourette Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Tourette Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Tourette Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Tourette Syndrome (Central Nervous System)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Tourette Syndrome (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Tourette Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Tourette Syndrome - Overview
- Tourette Syndrome - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Tourette Syndrome - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Tourette Syndrome - Companies Involved in Therapeutics Development
- Asarina Pharma AB
- Emalex Biosciences Inc
- Evero Health Ltd
- Noema Pharma AG
- Octapharma AG
- SOM Biotech SL
- Tourette Syndrome - Drug Profiles
- bevantolol - Drug Profile
- Product Description
- Mechanism Of Action
- dronabinol + palmidrol - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ecopipam hydrochloride - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- immune globulin (human) - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events

NOE-105 - Drug Profile

Product Description

Mechanism Of Action

History of Events

sepranolone - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Antagonize DRD2 for CNS Disorders and Hormonal Disorders - Drug Profile

Product Description

Mechanism Of Action

Tourette Syndrome - Dormant Projects

Tourette Syndrome - Discontinued Products

Tourette Syndrome - Product Development Milestones

Featured News & Press Releases

Feb 16, 2022: First patient in for landmark Tourette Syndrome study

Jan 18, 2022: SciSparc advances its phase IIb clinical trial in patients with Tourette syndrome with its proprietary drug candidate SCI-110

Dec 22, 2021: Asarina Pharma receives final approval for landmark phase IIa Tourette study

Dec 08, 2021: Noema Pharma hosting key opinion leader webinar on Stuttering

Nov 10, 2021: Paragon's portfolio company Emalex Biosciences announces positive topline results from phase 2b clinical study evaluating ecopipam for pediatric Tourette syndrome

Sep 16, 2021: Administrative backlog at public authority causes short-term delay in Tourette study

Aug 05, 2021: Noema Pharma initiates phase 2a Allevia study of PDE10A inhibitor NOE-105 in Tourette Syndrome

Jul 26, 2021: SciSparc announces updates regarding its phase IIb study in Tourette Syndrome

Jun 22, 2021: Emalex Biosciences announces completion of patient enrollment in phase 2b clinical trial evaluating Ecopipam (EBS-101) for pediatric patients with Tourette Syndrome

Jun 08, 2021: Asarina Pharma granted US patent for Sepranolone for Tourette syndrome, OCD and pathological gambling

May 19, 2021: Asarina Pharma receives approval of CTA for phase IIa Tourette study

Feb 11, 2021: New preclinical study confirms that Sepranolone suppresses tics in Tourette Syndrome

Feb 10, 2021: SciSparc engages Procaps for development and production of CannAmide and its SCI-110 product candidate

Sep 01, 2020: Emalex Biosciences Phase 2b Tourette Syndrome clinical trial reaches enrollment milestone

Mar 24, 2020: Asarina Pharma to release historic Phase IIb PMDD data on schedule

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Tourette Syndrome, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Tourette Syndrome - Pipeline by Asarina Pharma AB, 2022
Tourette Syndrome - Pipeline by Emalex Biosciences Inc, 2022
Tourette Syndrome - Pipeline by Evero Health Ltd, 2022
Tourette Syndrome - Pipeline by Noema Pharma AG, 2022
Tourette Syndrome - Pipeline by Octapharma AG, 2022
Tourette Syndrome - Pipeline by SOM Biotech SL, 2022
Tourette Syndrome - Dormant Projects, 2022
Tourette Syndrome - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Tourette Syndrome, 2022

Number of Products under Development by Companies, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

I would like to order

Product name: Tourette Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/T32C09C0F7C3EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T32C09C0F7C3EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

